These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15971636)

  • 1. [Assessment of metabolic impairments inducted by atypical antipsychotics among schizophrenic patients].
    Gauthé M; Goldberger C; Olié JP; Lôo H; Gury C; Poirier MF
    Encephale; 2005; 31(1 Pt 1):18-23. PubMed ID: 15971636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Schizophrenia, diabetes mellitus and antipsychotics].
    Gury C
    Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan.
    Huang TL; Chen JF
    Schizophr Res; 2005 Dec; 80(1):55-9. PubMed ID: 15964176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics and glucose homeostasis.
    Bergman RN; Ader M
    J Clin Psychiatry; 2005 Apr; 66(4):504-14. PubMed ID: 15816794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
    Newcomer JW
    J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study.
    Saari K; Koponen H; Laitinen J; Jokelainen J; Lauren L; Isohanni M; Lindeman S
    J Clin Psychiatry; 2004 Apr; 65(4):547-50. PubMed ID: 15119919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

  • 10. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
    Citrome L; Kalsekar I; Baker RA; Hebden T
    Curr Med Res Opin; 2014 Aug; 30(8):1629-41. PubMed ID: 24666104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of treatment with atypical antipsychotics.
    Kane JM; Barrett EJ; Casey DE; Correll CU; Gelenberg AJ; Klein S; Newcomer JW
    J Clin Psychiatry; 2004 Nov; 65(11):1447-55. PubMed ID: 15554755
    [No Abstract]   [Full Text] [Related]  

  • 12. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care.
    Nasrallah HA; Newcomer JW
    J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S7-14. PubMed ID: 15356415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective.
    Chue P
    Can J Psychiatry; 2004 Mar; 49(3):200-7. PubMed ID: 15101503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia and atypical antipsychotic drugs.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 18():27-35. PubMed ID: 15600382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia and comorbid metabolic disorders.
    Henderson DC
    J Clin Psychiatry; 2005; 66 Suppl 6():11-20. PubMed ID: 16107179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum free Fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics.
    Wang CJ; Zhang ZJ; Sun J; Zhang XB; Mou XD; Zhang XR; Shang XF; Zhang TQ
    Biol Psychiatry; 2006 Dec; 60(12):1309-13. PubMed ID: 16650386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia, antipsychotics and metabolic disease.
    Reynolds GP
    J Psychopharmacol; 2007 Jun; 21(4):355-6. PubMed ID: 17656424
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hyperlipidemia - side-effect of "Atypical" neuroleptics?].
    Wetterling T
    Fortschr Neurol Psychiatr; 2003 Oct; 71(10):535-40. PubMed ID: 14551854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
    Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS;
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.